Abstract:Background: Oligo-astheno-teratospermia (sperm of low concentration, reduced motility and increased abnormal morphology)of unknown cause is common and the need for treatment is felt by patients and doctors alike. As a result, a variety of empirical, non-specific treatments have been used in an attempt to improve semen characteristics and fertility.Whilst bromocriptine treatment for reducing prolactin levels in hyperprolactinaemic males (as in females), and, in the treatment of hypogonadotropic hypogonadism with hyperprolactinaemia, is beneficial, it has also been used for oligospermic men in the absence of any endocrinopathy. Prolactin may play a direct role in spermatogenesis and hormone production. It has also been claimed that in oligospermic men with normal gonadotrophins mean prolactin levels are higher and that hyperprolactinaemia is more common compared to fertile men. It has been proposed that the administration of bromocriptine under these circumstances might counteract a prolactin-induced block on the action of gonadotrophins on the testicles and, subsequently, that the reduction in prolactin levels might lead to an improvement in semen parameters and fertility. Although it is not licensed for use in male infertility, bromocriptine has been used for normogonadotrophic individuals with oligospermia and normal or slightly elevated prolactin levels. This review considers the available evidence of the effect of bromocriptine therapy for normoprolactinaemic males with idiopathic oligo and/or asthenospermia. Objectives: The objective of this review was to assess the effects of bromocriptine on pregnancy rates among couples where subfertility has been attributed to idiopathic oligo- and/or asthenospermia. Search strategy: The Cochrane Subfertility Review Group specialised register of controlled trials was searched". Selection criteria: Randomised trials of oral bromocriptine versus placebo or no treatment for couples with subfertility attributed to male factor. Data collection and analysis: Data were extracted by one reviewer and any disagreements were resolved by discussion with other reviewers. Main results: Four studies were included. The method of randomisation was not specified in any of the trials, which were all of crossover design. Compared with placebo, bromocriptine was associated with a significant reduction in serum prolactin levels (weighted mean difference -195.3 micro international units per litre, 95% confidence interval -276.5 to -114). No effects on sperm parameters were seen. There was also no effect on pregnancy rates observed between bromocriptine and placebo (0.70 odds ratio, 95% confidence interval 0.15 to 3.24). Authors' conclusions: Bromocriptine appears to reduce prolactin levels in subfertile men with normal gonadotrophic function. There is not enough evidence to show that bromocriptine is helpful in improving fertility.[This abstract was prepared centrally.].

[Effects of bromocriptine on the treatment of prolactinomas in male patients and its influences on their sexual function]

The effect of bromocriptine treatment on sexual functioning and depressive symptoms in women with mild hyperprolactinemia

[Bromocriptine monotherapy of a prolactinoma causing erectile dysfunction]

Sexual Functioning in Hyperprolactinemic Patients Treated With Cabergoline or Bromocriptine

Long-term bromocriptine therapy may restore the inhibitory control of prolactin release in some patients with pathological hyperprolactinemia

Treatment of sexual dysfunction induced by hyperprolactinemia accompanied by reduced luteinizing hormone levels: A case report

[Efficacy of compound xuanju capsule combined with bromocriptine on hyperprolactinemia-induced erectile dysfunction]

STUDY OF THE EFFECTS OF BROMOCRIPTINE ON SEXUAL IMPOTENCE

Lack of effect of bromocriptine on semen quality in men with normal or slightly elevated prolactin levels

Analysis of the Correlation Between Bromocriptine and Consistence and Apoplexy of Prolactinomas

Clinical management and outcome of 36 invasive prolactinomas treated with dopamine agonist

[Prolactinoma in the male. Physiopathological, clinical, and therapeutic features]

Effects of Transsphenoidal Approach on the Gonadal Function of Adult Male Prolactinoma Patients (A Report of 70 Cases)

WITHDRAWN: Bromocriptine for idiopathic oligo/asthenospermia

Bromocriptine for idiopathic oligo/asthenospermia

Impaired Cardiometabolic Effects of Bromocriptine in Men With Early-Onset Androgenic Alopecia

[Analysis of therapeutic outcomes of polycystic ovary syndrome patients with hyperprolactinemia]

Medical treatment of prolactinomas

Five years follow-up of invasive prolactinomas with special reference to the control of cavernous sinus invasion

Oral and injectable long-lasting bromocriptine preparations in hyperprolactinemia: comparison of their prolactin lowering activity, tolerability and safety

A prospective, double-blind, randomized, placebo-controlled clinical trial of bromocriptin in clomiphene-resistant patients with polycystic ovary syndrome and normal prolactin level